User Fees Collection Better Than Expected; Reserve Fund Could Lower FY '12 Fees
This article was originally published in The Pink Sheet Daily
Executive Summary
Manufacturer user fees paid for about 60% of FDA's drug review costs in fiscal year 2009.
You may also be interested in...
FDA Expects Sharp Drop In Drug Applications This Year
Announcing the PDUFA fees for fiscal 2011, agency says it expects to receive 117.5 fee-paying full application equivalents in the current fiscal year, down 16 percent from the 2009 level.
FDA Receives Assurances That PDUFA Remains Priority on Capitol Hill
As Congress prepared to adjourn for summer recess without reauthorizing the Prescription Drug User Fee Act, FDA Commissioner Andrew von Eschenbach sent an e-mail to agency employees Aug. 3 designed to lessen worries about job security
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.